Raseglurant

Raseglurant
Clinical data
ATC code	None;
Identifiers
	IUPAC name 2-[(3-Fluorophenyl)ethynyl]-4,6-dimethyl-3-pyridinamine;
CAS Number	757950-09-7;
PubChem CID	10331863;
ChemSpider	8507323;
UNII	66UCJ8Z8L1;
CompTox Dashboard (EPA)	DTXSID40226707 ;
Chemical and physical data
Formula	C15H13FN2
Molar mass	240.281 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc2cccc(C#Cc1nc(cc(c1N)C)C)c2;
	InChI InChI=1S/C15H13FN2/c1-10-8-11(2)18-14(15(10)17)7-6-12-4-3-5-13(16)9-12/h3-5,8-9H,17H2,1-2H3; Key:MEDCLNYIYBERKO-UHFFFAOYSA-N;

Raseglurant (INN) (code name ADX-10059) is a negative allosteric modulator of the mGlu₅ receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety.^[1]^[2]^[3] It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.^[3]^[4]^[5]

References

^ Célanire S, Duvey G, Poli S, Rocher JP (January 2012). "mGluR2 activators and mGluR5 blockers advancing in the clinic for major CNS disorders.". Annual Reports in Medicinal Chemistry. Vol. 47. Academic Press. pp. 71–88. ISBN 978-0-12-397214-9.
^ "Don't Dodge the Dentist – Tips for Dealing with Dental Anxiety". Retrieved 2017-04-05.
^ ^a ^b Stein MB, Steckler T (30 July 2010). Behavioral Neurobiology of Anxiety and Its Treatment. Springer Science & Business Media. pp. 397–. ISBN 978-3-642-02912-7.
^ Dominguez C (18 November 2010). Neurodegenerative Diseases. Springer Science & Business Media. pp. 120–. ISBN 978-3-642-16758-4.
^ Shaheen NJ (25 March 2013). Benign and Neoplastic Conditions of the Esophagus, An Issue of Gastroenterology Clinics. Elsevier Health Sciences. pp. 119–. ISBN 978-1-4557-7175-2.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.